CR9968A - METHODS AND COMPOSITIONS TO BE USED IN THE TREATMENT OF PATIENTS WITH POSITIVE AUTOANTIBODY DISEASES - Google Patents
METHODS AND COMPOSITIONS TO BE USED IN THE TREATMENT OF PATIENTS WITH POSITIVE AUTOANTIBODY DISEASESInfo
- Publication number
- CR9968A CR9968A CR9968A CR9968A CR9968A CR 9968 A CR9968 A CR 9968A CR 9968 A CR9968 A CR 9968A CR 9968 A CR9968 A CR 9968A CR 9968 A CR9968 A CR 9968A
- Authority
- CR
- Costa Rica
- Prior art keywords
- treatment
- patients
- methods
- compositions
- patient
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000002299 complementary DNA Substances 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invencion se refiere a metodos y composiciones para usarse en el tratamiento de pacientes con enfermedad de autoanticuerpo positivo; tratamiento de un paciente que tiene un titulo de ANA fr 1:80 o mayor, o 30 Ul/ml o mas anticuerpos anti-ADNdc en su plasma o suero sanguineo, que comprende administrar una cantidad terapeuticamente efectiva de un agente inmunomodulador, tal como un antagonista de neutrocina-alfa; ademas se provee un metodo para reducir la frecuencia o cantidad de corticosteroide administrado a los pacientes; en modalidades preferidas, el paciente tiene lupus eritematoso sistemico; tambien se proveen metodos para determinar si un paciente de lupus esta respondiendo al tratamiento medico.The present invention relates to methods and compositions for use in the treatment of patients with positive autoantibody disease; treatment of a patient who has an ANA titer fr 1:80 or greater, or 30 Ul / ml or more anti-cDNA antibodies in their plasma or blood serum, which comprises administering a therapeutically effective amount of an immunomodulatory agent, such as a neutrocin-alpha antagonist; In addition, a method is provided to reduce the frequency or amount of corticosteroid administered to patients; in preferred embodiments, the patient has systemic lupus erythematosus; Methods are also provided to determine if a lupus patient is responding to medical treatment.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72562505P | 2005-10-13 | 2005-10-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR9968A true CR9968A (en) | 2008-08-18 |
Family
ID=41003475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR9968A CR9968A (en) | 2005-10-13 | 2008-05-12 | METHODS AND COMPOSITIONS TO BE USED IN THE TREATMENT OF PATIENTS WITH POSITIVE AUTOANTIBODY DISEASES |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN101512007A (en) |
| CR (1) | CR9968A (en) |
| UA (1) | UA99094C2 (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102533996B (en) * | 2012-01-04 | 2013-06-05 | 南通大学附属医院 | Method for determining APRIL (A Proliferation-inducing Ligand) gene promoter and transcription factor binding site and use |
| CN105693846A (en) * | 2014-07-13 | 2016-06-22 | 马海龙 | Aptamer NKXA10 specifically for Neutrokine-alpha protein and application of aptamer NKXA10 |
| CN105732804A (en) * | 2014-07-13 | 2016-07-06 | 马海龙 | Aptamer NKXA4 specifically aiming at Neutrokine-alpha protein and application thereof |
| CN105732802A (en) * | 2014-07-13 | 2016-07-06 | 马海龙 | Aptamer NKXA11 specifically aiming at Neutrokine-alpha protein and application thereof |
| CN105732799A (en) * | 2014-07-13 | 2016-07-06 | 马海龙 | Aptamer NKXA18 specifically aiming at Neutrokine-alpha protein and application thereof |
| CN105753967A (en) * | 2014-07-13 | 2016-07-13 | 马海龙 | Nucleic acid aptamer NKXA14 specifically aiming at Neutrokine-alpha protein and application thereof |
| CN105713083A (en) * | 2014-07-13 | 2016-06-29 | 马海龙 | Specific aptamer NKXA17 for Neutrokine-alpha protein and application of specific aptamer NKXA17 |
| CN105693849A (en) * | 2014-07-13 | 2016-06-22 | 马海龙 | Aptamer NKXA5 specifically for Neutrokine-alpha protein and application of aptamer NKXA5 |
| CN105693848A (en) * | 2014-07-13 | 2016-06-22 | 马海龙 | Aptamer NKXA7 specifically for Neutrokine-alpha protein and application of aptamer NKXA7 |
| CN105693847A (en) * | 2014-07-13 | 2016-06-22 | 马海龙 | Aptamer NKXA9 specifically for Neutrokine-alpha protein and application of aptamer NKXA9 |
| CN105732801A (en) * | 2014-07-13 | 2016-07-06 | 马海龙 | Aptamer NKXA13 specifically aiming at Neutrokine-alpha protein and application thereof |
| CN104177488B (en) * | 2014-07-13 | 2016-09-14 | 北京博奥医学检验所有限公司 | A nucleic acid aptamer specific for Neutrokine-α protein and its application |
| CN105732800A (en) * | 2014-07-13 | 2016-07-06 | 马海龙 | Aptamer NKXA15 specifically aiming at Neutrokine-alpha protein and application thereof |
| CN105732803A (en) * | 2014-07-13 | 2016-07-06 | 马海龙 | Aptamer NKXA6 specifically aiming at Neutrokine-alpha protein and application thereof |
| WO2016128318A1 (en) * | 2015-02-09 | 2016-08-18 | Ucb Biopharma Sprl | Pharmaceutical formulation |
| CN113075410B (en) * | 2021-03-29 | 2022-08-16 | 广州市妇女儿童医疗中心 | Application of anti-nRNP/Sm antibody as diagnosis marker of congenital megacolon |
| CN113075400B (en) * | 2021-03-29 | 2022-07-22 | 广州市妇女儿童医疗中心 | Application of anti-double-stranded DNA antibody as a diagnostic marker for Hirschsprung's disease |
-
2006
- 2006-10-05 UA UAA200806028A patent/UA99094C2/en unknown
- 2006-10-05 CN CNA2006800471107A patent/CN101512007A/en active Pending
-
2008
- 2008-05-12 CR CR9968A patent/CR9968A/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| UA99094C2 (en) | 2012-07-25 |
| CN101512007A (en) | 2009-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR9968A (en) | METHODS AND COMPOSITIONS TO BE USED IN THE TREATMENT OF PATIENTS WITH POSITIVE AUTOANTIBODY DISEASES | |
| NZ597082A (en) | Methods and Compositions for Use in Treatment of Patients with Autoantibody Positive Diseases | |
| AR049985A1 (en) | COMBINATION TREATMENT FOR NON-HEMATOLOGICAL MALIGNAL DISEASES | |
| Nagata et al. | Favipiravir: a new medication for the Ebola virus disease pandemic | |
| AR041725A1 (en) | PREVENTION, TREATMENT OF SINUCLEINOPATIC DISEASE AND PHARMACOLOGICAL COMPOSITION | |
| AR024074A1 (en) | ABETA FRAGMENT JOINED WITH A BEARING PEPTIDE TO PREVENT OR TREAT DISEASES ASSOCIATED WITH ABETA AMILOID DEPOSITS, PHARMACEUTICAL COMPOSITIONS CONTAINING IT, AND ITS USE IN THE PREPARATION OF MEDICINES. | |
| BR0211474A (en) | Use of biologically active hiv-1 tat, fragments or derivatives thereof, to target and / or activate antigen presenting cells, and / or to provide charge molecules for vaccination and / or preventive or therapeutic treatment of other diseases. | |
| MX2022011111A (en) | Methods for treating coronavirus infection and resulting inflammation-induced lung injury. | |
| BRPI0407485A (en) | use of anti-insulin-like growth factor i receptor antibodies | |
| NZ624059A (en) | Therapeutic applications of activation of human antigen-presenting cells through dectin-1 | |
| NO20074999L (en) | Method and preparation for the treatment of peripheral vascular diseases | |
| NI201100147A (en) | METHODS TO TREAT ACUTE MYOCARDIAL INFARCTIONS AND RELATED DISORDERS. | |
| BRPI0511235A (en) | topical preparation and method for transdermal administration and localization of therapeutic agents | |
| AR061350A1 (en) | EXTENDED REGIME OF PROGRESSIVE REDUCTION OF STROGENS | |
| BR112013005673A2 (en) | use of lysosomal acid lipase for treatment of lysosomal acid lipase deficiency in patients | |
| EP1543158A4 (en) | TH RAPEUTICAL COMPOSITIONS APTAMIC R GUL ES | |
| EA200700214A1 (en) | MEMANTINE AS AN ADDITIONAL THERAPY FOR ATYPICAL ANTIPSYCHOTIC REMEDIES IN PATIENTS WITH SCHIZOPHRENIA | |
| EA200801698A1 (en) | DRUG COMPOSITIONS FOR APPLICATION IN VAGIN | |
| WO2004026260A3 (en) | Prophylactic and therapeutic hiv aptamers | |
| CY1110369T1 (en) | NEW COOPERATIVE COMBINATION THAT INCLUDES Roflumilast And Formoterol | |
| EA201690057A1 (en) | OSTEOPONTIN MILK MAMMALS TO IMPROVE IMMUNOLOGICAL REACTIVITY | |
| BR0313413A (en) | Use of beta amyloid vaccination together with a selective cox-2 inhibitor for the treatment of alzheimer's disease | |
| BR112012020185A2 (en) | use of oral heparin preparations to treat urinary tract diseases and disorders. | |
| EA200401303A1 (en) | MEDICINES CONTAINING STEROIDS AND NEW ANTICHOLINERGIC MEANS | |
| BRPI0414518A (en) | pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d and parathyroid hormone derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |